Attention deficit hyperactivity disorder (ADHD) is the most commonly
diagnosed psychiatric disorder of childhood, estimated to affect 3 to 5
percent of school-aged children. Research shows that ADHD tends to run in
families. Its core symptoms include developmentally inappropriate levels
of attention, concentration, activity, distractibility, and impulsivity.
Children with ADHD usually have impaired functioning in peer relationships
and multiple settings including home and school. ADHD has also been shown
to have long-term adverse effects on academic performance, vocational
success, and social-emotional development.
Psychostimulant medications, including methylphenidate (Ritalin®),
amphetamine (Dexedrine ® and Adderall ®), and pemoline (Cylert ®), are
by far the most widely researched and commonly prescribed treatments for
ADHD. Numerous short-term studies have established the safety and efficacy
of stimulants and psychosocial treatments for alleviating the symptoms of
ADHD. A multisite study of children with ADHD recently concluded that the
two most effective treatment modalities for elementary school children
with ADHD are a closely monitored medication treatment and a treatment
that combines medication with intensive behavioral interventions. Another
study, jointly funded by the NIMH and the National Institute on Drug
Abuse, has shown that boys with ADHD who are treated with stimulants are
significantly less likely to abuse drugs and alcohol when they get older.
In previous studies, these same researchers found that nearly twice as
many adults with ADHD (that was generally not diagnosed or treated until
much later in life) also abused drugs and/or alcohol at some point in
their lives, compared to adults without ADHD.
Information
provided by the National Institute of Mental Health